Clinical Trial Update: An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 study evaluating vorinostat for moderate-to-severe Crohn's disease with ustekinumab maintenance therapy; the trial is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Crohn's Disease | Phase 1, Phase 2 | Status: RECRUITING